{"id":515211,"date":"2021-07-20T12:37:05","date_gmt":"2021-07-20T16:37:05","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/agilent-pd-l1-ihc-22c3-pharmdx-expands-ce-ivd-mark-in-non-small-cell-lung-cancer-nsclc\/"},"modified":"2021-07-20T12:37:05","modified_gmt":"2021-07-20T16:37:05","slug":"agilent-pd-l1-ihc-22c3-pharmdx-expands-ce-ivd-mark-in-non-small-cell-lung-cancer-nsclc","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/agilent-pd-l1-ihc-22c3-pharmdx-expands-ce-ivd-mark-in-non-small-cell-lung-cancer-nsclc\/","title":{"rendered":"Agilent PD-L1 IHC 22C3 pharmDx Expands CE-IVD mark in Non-small Cell Lung Cancer (NSCLC)"},"content":{"rendered":"

<\/p>\n

Agilent PD-L1 IHC 22C3 pharmDx Expands CE-IVD mark in Non-small Cell Lung Cancer (NSCLC)<\/b><\/p>\n

\nCompanion diagnostic can help guide treatment decisions in cases of NSCLC\n<\/p>\n

SANTA CLARA, Calif.–(BUSINESS WIRE<\/a>)–Agilent Technologies Inc.<\/a> (NYSE: A) today announced that the company\u2019s PD-L1 IHC 22C3 pharmDx assay is now labeled for expanded use in patients with non-small cell lung cancer (NSCLC) in the European Union. PD-L1 IHC 22C3 pharmDx can now be used as an aid in identifying NSCLC patients with tumor PD-L1 expression of Tumor Proportion Score (TPS) \u2265 50% for treatment with Libtayo\u00ae (cemiplimab). This announcement underscores Agilent’s continuing commitment to the development of IHC-based diagnostics for cancer therapy.\n<\/p>\n

\nLung cancer is the leading cause of cancer death overall and the 2nd<\/sup> most commonly diagnosed cancer in Europe.1<\/sup> NSCLC makes up approximately 85% of all lung cancer cases.2<\/sup> In Europe, the average five-year survival rate for lung cancer is less than 20%.3 <\/sup><\/p>\n

\n\u201cThis expanded indication for PD-L1 IHC 22C3 pharmDx will enable pathologists in Europe to identify patients with NSCLC who may be eligible for treatment with Libtayo,\u201d said Sam Raha, president of Agilent’s Diagnostics and Genomics Group. \u201cThis further demonstrates Agilent\u2019s commitment to partnering with leading pharmaceutical companies to develop IHC-based diagnostics for targeted cancer therapy.\u201d\n<\/p>\n

\nAnti-PD-1 immunotherapies such as Libtayo offer new treatment options for patients with advanced NSCLC.4<\/sup> Sanofi and Regeneron developed Libtayo and partnered with Agilent for the use of PD-L1 IHC 22C3 pharmDx to evaluate PD-L1 expression in patients in the pivotal EMPOWER-Lung 1 (Study 1624)clinical trial.4 <\/sup><\/p>\n

\nLibtayo is a fully-human monoclonal antibody targeting the immune checkpoint receptor PD-1 on T-cells. By binding to PD-1, Libtayo has been shown to block cancer cells from using the PD-1 pathway to suppress T-cell activation.4 <\/sup><\/p>\n

About Agilent Technologies<\/b><\/p>\n

\nAgilent Technologies Inc. (NYSE: A) is a global leader in life sciences, diagnostics, and applied chemical markets, delivering insight and innovation toward improving the quality of life. Agilent instruments, software, services, solutions, and people provide trusted answers to customers’ most challenging questions. The company generated revenue of $5.34 billion in fiscal 2020 and employs 16,400 people worldwide. Information about Agilent is available at www.agilent.com<\/a>. To receive the latest Agilent news, subscribe to the Agilent Newsroom<\/a>. Follow Agilent on LinkedIn<\/a>, Twitter<\/a>, and Facebook<\/a>.\n<\/p>\n

References:<\/i><\/b><\/p>\n

    \n
  1. World Health Organization. Global Cancer Observatory. https:\/\/gco.iarc.fr\/today\/data\/factsheets\/populations\/908-europe-fact-sheets.pdf<\/a> (accessed February 26, 2021).<\/i><\/li>\n
  2. Wood, R.; Taylor-Stokes, G.; Smith, F.; Chaib, C. The Humanistic Burden of Advanced Non-Small Cell Lung Cancer (NSCLC) in Europe: A Real-World Survey Linking Patient Clinical Factors to Patient and Caregiver Burden. Qual. Life Res. 2019, 28 (7), 1849\u20131861<\/i><\/li>\n
  3. Lung Cancer Europe. 4th LuCE report on lung cancer: Early diagnosis and screening challenges in lung cancer. https:\/\/www.lungcancereurope.eu\/wp-content\/uploads\/2019\/11\/WEB-VERSION-IV-LuCE-Report.pdf.pdf<\/a> (accessed June 24, 2021).<\/i><\/li>\n
  4. Libtayo [Summary of Product Characteristics]. European Medicines Agency; 2021. <\/i>\n

    \n\u00a0\n<\/p>\n<\/li>\n<\/ol>\n

    \"\"<\/p>\n

    View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20210720006000\/en\/<\/a><\/span><\/p>\n

    Media Contact
    \n<\/b>
    Naomi Goumillout
    \n
    Agilent Technologies
    \n
    +1.781.266.2819
    \n
    naomi.goumillout@agilent.com<\/a><\/p>\n

    KEYWORDS:<\/b> United States North America California<\/p>\n

    INDUSTRY KEYWORDS:<\/b> Health Science Pharmaceutical Research Oncology<\/p>\n

    MEDIA:<\/b><\/p>\n\n\n\n\n
    Logo<\/b><\/font><\/td>\n<\/tr>\n
    \"Logo\"<\/td>\n<\/tr>\n
    <\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

    Agilent PD-L1 IHC 22C3 pharmDx Expands CE-IVD mark in Non-small Cell Lung Cancer (NSCLC) Companion diagnostic can help guide treatment decisions in cases of NSCLC SANTA CLARA, Calif.–(BUSINESS WIRE)–Agilent Technologies Inc. (NYSE: A) today announced that the company\u2019s PD-L1 IHC 22C3 pharmDx assay is now labeled for expanded use in patients with non-small cell lung cancer (NSCLC) in the European Union. PD-L1 IHC 22C3 pharmDx can now be used as an aid in identifying NSCLC patients with tumor PD-L1 expression of Tumor Proportion Score (TPS) \u2265 50% for treatment with Libtayo\u00ae (cemiplimab). This announcement underscores Agilent’s continuing commitment to the development of IHC-based diagnostics for cancer therapy. Lung cancer is the leading cause of cancer death overall and the 2nd … <\/p>\n

    Continue reading “Agilent PD-L1 IHC 22C3 pharmDx Expands CE-IVD mark in Non-small Cell Lung Cancer (NSCLC)”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-515211","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nAgilent PD-L1 IHC 22C3 pharmDx Expands CE-IVD mark in Non-small Cell Lung Cancer (NSCLC) - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/agilent-pd-l1-ihc-22c3-pharmdx-expands-ce-ivd-mark-in-non-small-cell-lung-cancer-nsclc\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Agilent PD-L1 IHC 22C3 pharmDx Expands CE-IVD mark in Non-small Cell Lung Cancer (NSCLC) - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Agilent PD-L1 IHC 22C3 pharmDx Expands CE-IVD mark in Non-small Cell Lung Cancer (NSCLC) Companion diagnostic can help guide treatment decisions in cases of NSCLC SANTA CLARA, Calif.–(BUSINESS WIRE)–Agilent Technologies Inc. (NYSE: A) today announced that the company\u2019s PD-L1 IHC 22C3 pharmDx assay is now labeled for expanded use in patients with non-small cell lung cancer (NSCLC) in the European Union. PD-L1 IHC 22C3 pharmDx can now be used as an aid in identifying NSCLC patients with tumor PD-L1 expression of Tumor Proportion Score (TPS) \u2265 50% for treatment with Libtayo\u00ae (cemiplimab). This announcement underscores Agilent’s continuing commitment to the development of IHC-based diagnostics for cancer therapy. Lung cancer is the leading cause of cancer death overall and the 2nd … Continue reading "Agilent PD-L1 IHC 22C3 pharmDx Expands CE-IVD mark in Non-small Cell Lung Cancer (NSCLC)"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/agilent-pd-l1-ihc-22c3-pharmdx-expands-ce-ivd-mark-in-non-small-cell-lung-cancer-nsclc\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-07-20T16:37:05+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210720006000r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/agilent-pd-l1-ihc-22c3-pharmdx-expands-ce-ivd-mark-in-non-small-cell-lung-cancer-nsclc\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/agilent-pd-l1-ihc-22c3-pharmdx-expands-ce-ivd-mark-in-non-small-cell-lung-cancer-nsclc\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Agilent PD-L1 IHC 22C3 pharmDx Expands CE-IVD mark in Non-small Cell Lung Cancer (NSCLC)\",\"datePublished\":\"2021-07-20T16:37:05+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/agilent-pd-l1-ihc-22c3-pharmdx-expands-ce-ivd-mark-in-non-small-cell-lung-cancer-nsclc\\\/\"},\"wordCount\":511,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/agilent-pd-l1-ihc-22c3-pharmdx-expands-ce-ivd-mark-in-non-small-cell-lung-cancer-nsclc\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210720006000r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/agilent-pd-l1-ihc-22c3-pharmdx-expands-ce-ivd-mark-in-non-small-cell-lung-cancer-nsclc\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/agilent-pd-l1-ihc-22c3-pharmdx-expands-ce-ivd-mark-in-non-small-cell-lung-cancer-nsclc\\\/\",\"name\":\"Agilent PD-L1 IHC 22C3 pharmDx Expands CE-IVD mark in Non-small Cell Lung Cancer (NSCLC) - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/agilent-pd-l1-ihc-22c3-pharmdx-expands-ce-ivd-mark-in-non-small-cell-lung-cancer-nsclc\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/agilent-pd-l1-ihc-22c3-pharmdx-expands-ce-ivd-mark-in-non-small-cell-lung-cancer-nsclc\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210720006000r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2021-07-20T16:37:05+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/agilent-pd-l1-ihc-22c3-pharmdx-expands-ce-ivd-mark-in-non-small-cell-lung-cancer-nsclc\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/agilent-pd-l1-ihc-22c3-pharmdx-expands-ce-ivd-mark-in-non-small-cell-lung-cancer-nsclc\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/agilent-pd-l1-ihc-22c3-pharmdx-expands-ce-ivd-mark-in-non-small-cell-lung-cancer-nsclc\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210720006000r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210720006000r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/agilent-pd-l1-ihc-22c3-pharmdx-expands-ce-ivd-mark-in-non-small-cell-lung-cancer-nsclc\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Agilent PD-L1 IHC 22C3 pharmDx Expands CE-IVD mark in Non-small Cell Lung Cancer (NSCLC)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Agilent PD-L1 IHC 22C3 pharmDx Expands CE-IVD mark in Non-small Cell Lung Cancer (NSCLC) - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/agilent-pd-l1-ihc-22c3-pharmdx-expands-ce-ivd-mark-in-non-small-cell-lung-cancer-nsclc\/","og_locale":"en_US","og_type":"article","og_title":"Agilent PD-L1 IHC 22C3 pharmDx Expands CE-IVD mark in Non-small Cell Lung Cancer (NSCLC) - Market Newsdesk","og_description":"Agilent PD-L1 IHC 22C3 pharmDx Expands CE-IVD mark in Non-small Cell Lung Cancer (NSCLC) Companion diagnostic can help guide treatment decisions in cases of NSCLC SANTA CLARA, Calif.–(BUSINESS WIRE)–Agilent Technologies Inc. (NYSE: A) today announced that the company\u2019s PD-L1 IHC 22C3 pharmDx assay is now labeled for expanded use in patients with non-small cell lung cancer (NSCLC) in the European Union. PD-L1 IHC 22C3 pharmDx can now be used as an aid in identifying NSCLC patients with tumor PD-L1 expression of Tumor Proportion Score (TPS) \u2265 50% for treatment with Libtayo\u00ae (cemiplimab). This announcement underscores Agilent’s continuing commitment to the development of IHC-based diagnostics for cancer therapy. Lung cancer is the leading cause of cancer death overall and the 2nd … Continue reading \"Agilent PD-L1 IHC 22C3 pharmDx Expands CE-IVD mark in Non-small Cell Lung Cancer (NSCLC)\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/agilent-pd-l1-ihc-22c3-pharmdx-expands-ce-ivd-mark-in-non-small-cell-lung-cancer-nsclc\/","og_site_name":"Market Newsdesk","article_published_time":"2021-07-20T16:37:05+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210720006000r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/agilent-pd-l1-ihc-22c3-pharmdx-expands-ce-ivd-mark-in-non-small-cell-lung-cancer-nsclc\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/agilent-pd-l1-ihc-22c3-pharmdx-expands-ce-ivd-mark-in-non-small-cell-lung-cancer-nsclc\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Agilent PD-L1 IHC 22C3 pharmDx Expands CE-IVD mark in Non-small Cell Lung Cancer (NSCLC)","datePublished":"2021-07-20T16:37:05+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/agilent-pd-l1-ihc-22c3-pharmdx-expands-ce-ivd-mark-in-non-small-cell-lung-cancer-nsclc\/"},"wordCount":511,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/agilent-pd-l1-ihc-22c3-pharmdx-expands-ce-ivd-mark-in-non-small-cell-lung-cancer-nsclc\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210720006000r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/agilent-pd-l1-ihc-22c3-pharmdx-expands-ce-ivd-mark-in-non-small-cell-lung-cancer-nsclc\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/agilent-pd-l1-ihc-22c3-pharmdx-expands-ce-ivd-mark-in-non-small-cell-lung-cancer-nsclc\/","name":"Agilent PD-L1 IHC 22C3 pharmDx Expands CE-IVD mark in Non-small Cell Lung Cancer (NSCLC) - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/agilent-pd-l1-ihc-22c3-pharmdx-expands-ce-ivd-mark-in-non-small-cell-lung-cancer-nsclc\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/agilent-pd-l1-ihc-22c3-pharmdx-expands-ce-ivd-mark-in-non-small-cell-lung-cancer-nsclc\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210720006000r1&sid=flmnd&distro=nx&lang=en","datePublished":"2021-07-20T16:37:05+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/agilent-pd-l1-ihc-22c3-pharmdx-expands-ce-ivd-mark-in-non-small-cell-lung-cancer-nsclc\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/agilent-pd-l1-ihc-22c3-pharmdx-expands-ce-ivd-mark-in-non-small-cell-lung-cancer-nsclc\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/agilent-pd-l1-ihc-22c3-pharmdx-expands-ce-ivd-mark-in-non-small-cell-lung-cancer-nsclc\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210720006000r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210720006000r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/agilent-pd-l1-ihc-22c3-pharmdx-expands-ce-ivd-mark-in-non-small-cell-lung-cancer-nsclc\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Agilent PD-L1 IHC 22C3 pharmDx Expands CE-IVD mark in Non-small Cell Lung Cancer (NSCLC)"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/515211","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=515211"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/515211\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=515211"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=515211"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=515211"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}